Glutathione activation of an organometallic half-sandwich anticancer drug candidate by ligand attack
Related Experiment Video
Updated: Jan 3, 2026

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Xin Zhang1, Fortuna Ponte, Elisa Borfecchia
1Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK. p.j.sadler@warwick.ac.uk.
Abstract:
In contrast to the clinical drug cisplatin, the anticancer complex [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ [1-I] is inert towards hydrolysis and targets cancer cell metabolism rather than DNA. A combination of DFT calculations and X-ray absorption spectroscopy (XAS) suggests that hydrolytic activation of 1-I involves catalytic attack by the intracellular tripeptide glutathione (GSH) on the azo bond of the chelating ligand in the complex.
More Related Videos
14:57Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Drug Metabolism: Phase II Reactions
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Phase II Reactions: Glucuronidation
Targeted Cancer Therapies
There are several types of targeted therapies against...